Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy

Chimeric antigen receptor (CAR) T cells provide a therapeutic option in hematologic malignancies. However, treatment failure after initial response approaches 50%. In allogeneic hematopoietic cell transplantation, optimal fludarabine exposure improves immune reconstitution, resulting in lower nonrel...

Descripción completa

Detalles Bibliográficos
Autores principales: Fabrizio, Vanessa A., Boelens, Jaap Jan, Mauguen, Audrey, Baggott, Christina, Prabhu, Snehit, Egeler, Emily, Mavroukakis, Sharon, Pacenta, Holly, Phillips, Christine L., Rossoff, Jenna, Stefanski, Heather E., Talano, Julie-An, Moskop, Amy, Margossian, Steven P., Verneris, Michael R., Myers, Gary Douglas, Karras, Nicole A., Brown, Patrick A., Qayed, Muna, Hermiston, Michelle, Satwani, Prakash, Krupski, Christa, Keating, Amy K., Wilcox, Rachel, Rabik, Cara A., Chinnabhandar, Vasant, Kunicki, Michael, Goksenin, A. Yasemin, Mackall, Crystal L., Laetsch, Theodore W., Schultz, Liora M., Curran, Kevin J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006295/
https://www.ncbi.nlm.nih.gov/pubmed/34788386
http://dx.doi.org/10.1182/bloodadvances.2021006418

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006295/
https://www.ncbi.nlm.nih.gov/pubmed/34788386
http://dx.doi.org/10.1182/bloodadvances.2021006418

Ejemplares similares